NYSE:NVOPharmaceuticals
Novo Nordisk (NYSE:NVO) Valuation Check After Mixed Year To Date And 1 Year Share Returns
Recent share performance and business profile
Novo Nordisk (NYSE:NVO) has drawn investor attention after a mixed stretch for the stock, with the share price down 12.6% year to date yet up 16.5% over the past month.
The Denmark based pharmaceutical group reports US$327.8b in revenue and US$121.96b in net income, primarily from its Diabetes and Obesity Care segment, alongside a smaller Rare Disease business.
See our latest analysis for Novo Nordisk.
At a share price of US$45.80, Novo Nordisk...